Zydus Cadila launches Enmixamine liquid capsule Obnyx, which will reduce the price of the prostate cancer treatment by 2/3

Zydus Cadila has announced the launch of the anti-prostate cancer drug Enzalutamide, known as "Obnyx" in IndiaThe introduction of Obnyx can significantly reduce the cost of treatment by nearly 70 per cent, with a weekly cost of Rs 5,995 and a monthly treatment cost of less than Rs 27,000The current market price for the en-sullamine drug is between Rs70,000 and Rs 80,000 per monthIt's a huge financial burden for older prostate cancer patients, which requires long periods of timeThe introduction of Obnyx will enable many prostate cancer patients to stick to treatmentone of the important aspects of prostate cancer treatment is reducing the effects of androgens on the prostateMany patients need androgen receptor-targeted therapy like Enzalutamide, which blocks the growth and spread of prostate cancer cells by blocking the effects of androgensWhat's more, it is the preferred option for people with severe liver, heart and kidney diseases, which are common in older menEnmeluamine has the advantage of oral administrationZydus's Obnyx is a leader in other formulations on the market because it is an independently developed liquid softgel with high bioavailability, unlike the hard gelatin capsules on the marketprostate cancer is one of the leading cancers in Indian men, and the risk increases with ageAbout one in nine men has prostate cancer throughout their livesThe incidence of the disease is close to 60 per cent in men over 65 years of ageOther risk factors, such as obesity, family history and poor diet, have been identified as major factors contributing to the increased incidence of prostate cancer